MLMaurício F. de Lima

Maurício F. de Lima

*This is an algorithmically generated author record based on publicly available information.

Maurício F. de Lima has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Miniaturized Reaction Platforms in Drug Discovery: from Synthesis to Direct-to-Biology Screening

    by Claudia V. S. Crispim, Maurício F. de Lima, Ahmad Abubakar, Ravena R. P. da Silva, Tiago H. C. da Silva, Daniel G. Silva

    The increasing demand for faster, more efficient drug discovery has exposed fundamental limitations in conventional design-make-test-analyze workflows, particularly regarding scalability, resource consumption, and reliance on purification-intensive processes. Miniaturized synthetic platforms have emerged not merely as a technical refinement, but as a paradigm shift integrating chemical synthesis and biological evaluation. This review examines miniaturization as a framework enabling the direct coupling of compound generation and biological screening, with emphasis on direct-to-biology strategies. A systematic assessment of the literature reveals convergence toward simplified, high-efficiency reaction formats compatible with automation and minimal purification. These platforms rely on a limited set of robust transformations, with amide coupling accounting for 42% of reported reactions, followed by multicomponent reactions (15%), click chemistry (14%), carbonyl-amine transformations (12%), and nucleophilic aromatic substitution (9%), while metal-catalyzed reactions remain underrepresented (3%). This distribution reflects a preference for high-yielding, operationally simple, and biocompatible reactions that tolerate crude conditions and enable direct screening. The integration of analytical and computational tools supports real‑time decision-making and accelerates structure-activity relationship exploration. Notably, efforts remain concentrated in oncology and infectious diseases, with a clear absence of applications targeting parasitic neglected tropical diseases. Collectively, these approaches redefine early-stage drug discovery by compressing timelines and reducing costs.